DynPort to assess safety of infectious disease therapeutics
A division of IT services company CSC has won a contract to establish and operate a Phase 1 clinical trial unit for infectious disease therapeutics.
A division of IT services company CSC has won a contract to establish and operate a Phase 1 clinical trial unit for infectious disease therapeutics.
DynPort Vaccine Company LLC (DVC), which offers consultative services to the biotech and pharma sectors, has won a contract valued at approximately $32.3m (Euro 21m) over a seven-year period to assess the safety of therapeutics.
Investigational products tested could include measures to protect against viral (other than HIV), bacterial, parasitic and fungal pathogens, including NIAID priority biodefense pathogens and emerging and re-emerging infectious diseases.
The company received the award from the National Institute of Allergy and Infectious Diseases (NIAID) - part of the National Institutes of Health and will team up with Quintiles Transnational Corp. to complete this work.
Quintiles and DynPort will manage a Phase 1 clinical trial unit to assess the safety of investigational therapeutic products being studied by NIAID, and determine pharmacokinetic and pharmacodynamic properties of up to four new investigational products per year. As the prime contractor, DVC will provide overall project management, clinical operations management, quality assurance and co-development of protocols. Quintiles will provide Phase 1 clinical research and support services for the implementation and conduct of approved Phase 1 clinical trial protocols.
"DVC and Quintiles have an established history of successboth individually and as partnersin clinical trial management of medical countermeasures," said Dr Robert V. House, president of DVC. "DVC has successfully advanced eight products into clinical trials in the last 10 years. This represents an expansion of DVC's capabilities in pharmaceutical product development."
"Quintiles is pleased to expand our existing government contracting relationship with DVC," said Oren Cohen, senior vice president and managing director of Quintiles" Public Health and Government Services business. "Quintiles' portion of the work on this contract will take place in our new, state-of-the-art, 150-bed Phase 1 clinical research unit in Overland Park, Kan. The facility was dedicated in May 2007 and provides an ideal setting to perform multiple, concurrent clinical trials."
Work will be performed by DVC at its headquarters in Frederick. Maryland.